‘Transformative’ HIV PrEP shot slowly overcomes cost hurdles

HIV/AIDS activists heralded the support of a caller twice-yearly pre-exposure prophylaxis (PrEP) medicine past year, but these celebrations were tempered by insurers’ reluctance to screen its exorbitant cost.  In the months since, payers are coming around, and more patients person entree to this landmark advancement.  In June, the Food and Drug Administration approved Yeztugo, an injection of the cause lenacapavir, arsenic a form of HIV PrEP. The…